This page lists past opportunities from CIP.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Barbara Galen, M.S.N., C.R.N.P., C.N.M.T., NCI, Phone: 301-594-5225, Email: firstname.lastname@example.org
Lalitha Shankar, M.D., NCI, Phone: 301-496-9531, Email: email@example.com
Keyvan Farahani, Ph.D., NCI, Phone: 301-451-2651, Email: firstname.lastname@example.org
The goal of this Funding Opportunity Announcement (FOA) is to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) studies, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or Cooperative Groups.
Mechanism of support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism
See full description in NIH Guide:PAR-08-147
For instructions on the inclusion of clinical protocols in the PAR-08-147 application, see NOT-CA-10-019
Heng Xie, Ph.D.,, NCI, Phone: 301-496-8866, Email: email@example.com
This Funding Opportunity Announcement (FOA) is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application.
Mechanism of Support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism
See full description in NIH Guide:PAR-08-025
Houston Baker, Ph.D., Phone: 310-594-9117; E-mail: firstname.lastname@example.org
Laurence Clarke, Ph.D., Phone: 301-435-9190; E-mail: email@example.com
Robert Nordstrom, Ph.D., Phone: 301-594-9192; E-mail: firstname.lastname@example.org
Keyvan Farahani, Ph.D., Phone: 301-451-2651; E-mail: Farahani@mail.nih.gov
Guoying Liu, Ph.D., Phone: 301-594-5220; E-mail: email@example.com
Guilllermo Marquez, Ph.D., Phone 310-451-3896; E-mail: firstname.lastname@example.org
This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is an open competition initiative, designed to continue the efforts of the NCI to develop and translate cancer-relevant optical imaging technologies as a part of an overall imaging program for early cancer detection, diagnosis, therapeutic response, drug development, and image-guided therapy. This FOA stems from the previous initiative on optical imaging technology. However, the program structure and goals of the current FOA differ from those of the original program. Accordingly, all responses to this FOA will be considered new applications, with the main objective being to accelerate the translational research of in vivo multimodal imaging and/or spectroscopic platforms from the laboratory and pre-clinical level to the clinical level. Applications are sought from multi-disciplinary, multi-institutional research teams. After the awards, successful teams will become Centers that will be organized into an interactive network. The network will be called the "Network for Translational Research: Optical Imaging" (NTR). The purpose of NTR is to develop, optimize, and validate imaging technology platforms and methods so that they can enter single or multi-site clinical trials and eventually be incorporated into clinical practice. Applicants responding to this FOA must identify a specific cancer-relevant clinical goal and propose to develop and validate at least one multimodal imaging platform, as defined in this FOA, to address this clinical goal.
See full description in NIH Guide: RFA-CA-08-002